Literature DB >> 23271571

Simplified regional citrate anticoagulation using a calcium-containing replacement solution for continuous venovenous hemofiltration.

Ling Zhang1, Yujie Liao, Jin Xiang, Wei Qin, Xiaodong Wu, Yi Tang, Yingying Yang, Zhiwen Chen, Ping Fu.   

Abstract

Regional citrate anticoagulation (RCA) is not widely used because it requires complex therapeutic modalities, a specialized calcium-free replacement solution, and continuous intravenous calcium infusion. We designed a simplified protocol for RCA using a commercial calcium-containing replacement solution for continuous venovenous hemofiltration (CVVH). Thirty-six patients were treated with RCA-based pre-dilution CVVH using a calcium-containing replacement solution (ionized calcium 1.50 mmol/L). We pumped a 4 % trisodium citrate solution into the arterial line of extracorporeal circulation at a starting rate of 200 mL/h while adjusting the rate to achieve a post-filter ionized calcium level of between 0.25 and 0.5 mmol/L. The initial blood flow was set at 150 mL/min. The replacement solution was delivered at 35 mL/kg/h. We measured the serum and effluent citrate concentration during CVVH at 0, 24, 48, and 72 h. The mean hemofilter survival was 61.3 ± 21.6 h (range 14-122 h). The mean 4 % trisodium citrate solution pumped was 207 (190-230) mL/h, and the mean pre-filter and post-filter ionized calcium levels were 0.96-1.02 and 0.34-0.38 mmol/L, respectively. Ninety-two, 63, and 48 % of the hemofilters were patent at 24, 48, and 72 h. The mean serum citrate concentration was not significantly different at 24, 48, and 72 h. No bleeding episodes were found, and no patient showed the symptoms and signs of hypocalcemia or citrate toxicity. Our simplified RCA protocol using a calcium-containing replacement solution for CVVH is effective and safe, and obviates the need for a separate peripheral or central venous catheter for continuous intravenous calcium infusion.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23271571     DOI: 10.1007/s10047-012-0680-2

Source DB:  PubMed          Journal:  J Artif Organs        ISSN: 1434-7229            Impact factor:   1.731


  22 in total

1.  Detection of citrate overdose in critically ill patients on citrate-anticoagulated venovenous haemofiltration: use of ionised and total/ionised calcium.

Authors:  Andries J Bakker; E Christiaan Boerma; Halbe Keidel; Peter Kingma; Peter H J van der Voort
Journal:  Clin Chem Lab Med       Date:  2006       Impact factor: 3.694

2.  Regional citrate versus systemic heparin anticoagulation for continuous renal replacement in critically ill patients.

Authors:  Demetrios J Kutsogiannis; R T Noel Gibney; Daniel Stollery; Jun Gao
Journal:  Kidney Int       Date:  2005-06       Impact factor: 10.612

3.  Transfusion requirements during continuous veno-venous haemofiltration: -the importance of filter life.

Authors:  M W Cutts; A N Thomas; R Kishen
Journal:  Intensive Care Med       Date:  2000-11       Impact factor: 17.440

Review 4.  Acute renal failure and multiple organ dysfunction in the ICU: from renal replacement therapy (RRT) to multiple organ support therapy (MOST).

Authors:  C Ronco; R Bellomo
Journal:  Int J Artif Organs       Date:  2002-08       Impact factor: 1.595

5.  Regional citrate anticoagulation in continuous venovenous hemofiltration in critically ill patients with a high risk of bleeding.

Authors:  R Palsson; J L Niles
Journal:  Kidney Int       Date:  1999-05       Impact factor: 10.612

6.  Citrate clearance in children receiving continuous venovenous renal replacement therapy.

Authors:  Vimal Chadha; Uttam Garg; Bradley A Warady; Uri S Alon
Journal:  Pediatr Nephrol       Date:  2002-09-07       Impact factor: 3.714

7.  Low polymorphonuclear cell degranulation during citrate anticoagulation: a comparison between citrate and heparin dialysis.

Authors:  J C Bos; M P Grooteman; A J van Houte; M Schoorl; J van Limbeek; M J Nubé
Journal:  Nephrol Dial Transplant       Date:  1997-07       Impact factor: 5.992

8.  Continuous renal replacement therapy: a worldwide practice survey. The beginning and ending supportive therapy for the kidney (B.E.S.T. kidney) investigators.

Authors:  Shigehiko Uchino; Rinaldo Bellomo; Hiroshi Morimatsu; Stanislao Morgera; Miet Schetz; Ian Tan; Catherine Bouman; Ettiene Macedo; Noel Gibney; Ashita Tolwani; Heleen Oudemans-van Straaten; Claudio Ronco; John A Kellum
Journal:  Intensive Care Med       Date:  2007-06-27       Impact factor: 17.440

9.  Regional citrate versus heparin anticoagulation during venovenous hemofiltration in patients at low risk for bleeding: similar hemofilter survival but significantly less bleeding.

Authors:  Michiel G H Betjes; Daniella van Oosterom; Madelon van Agteren; Jaqueline van de Wetering
Journal:  J Nephrol       Date:  2007 Sep-Oct       Impact factor: 3.902

10.  Citrate vs. heparin for anticoagulation in continuous venovenous hemofiltration: a prospective randomized study.

Authors:  Mehran Monchi; Denis Berghmans; Didier Ledoux; Jean-Luc Canivet; Bernard Dubois; Pierre Damas
Journal:  Intensive Care Med       Date:  2003-11-05       Impact factor: 17.440

View more
  6 in total

1.  N-acetylcysteine infusion in preventing hepatotoxicity secondary to intravenous injection of household bleach.

Authors:  Anthony H Eidan; James Sira; Mark Bellamy
Journal:  J Intensive Care Soc       Date:  2015-03-18

Review 2.  Metabolic Strategies for Inhibiting Cancer Development.

Authors:  Philippe Icard; Mauro Loi; Zherui Wu; Antonin Ginguay; Hubert Lincet; Edouard Robin; Antoine Coquerel; Diana Berzan; Ludovic Fournel; Marco Alifano
Journal:  Adv Nutr       Date:  2021-07-30       Impact factor: 8.701

3.  A mode of CVVH with regional citrate anticoagulation compared to no anticoagulation for acute kidney injury patients at high risk of bleeding.

Authors:  Jianping Gao; Feng Wang; Yonggang Wang; Dan Jin; Liping Tang; Konghan Pan
Journal:  Sci Rep       Date:  2019-04-29       Impact factor: 4.379

4.  Regional citrate anticoagulation with a substitute containing calcium for continuous hemofiltration in children.

Authors:  Ke Bai; Chengjun Liu; Fang Zhou; Feng Xu; Hongxing Dang
Journal:  Medicine (Baltimore)       Date:  2019-10       Impact factor: 1.889

5.  Feasibility and efficacy of modified fixed citrate concentration protocol using only commercial preparations in critically ill patients: a prospective cohort study with a historical control group.

Authors:  Yan Shi; Han-Yu Qin; Jin-Min Peng; Xiao-Yun Hu; Bin Du
Journal:  BMC Anesthesiol       Date:  2021-03-30       Impact factor: 2.217

6.  Reliability of monitoring acid-base and electrolyte parameters through circuit lines during regional citrate anticoagulation-continuous renal replacement therapy.

Authors:  Fang Wang; Mingjin Dai; Yuliang Zhao; Yingying Yang; Zhiwen Chen; Li Lin; Xue Tang; Ling Zhang
Journal:  Nurs Crit Care       Date:  2021-08-11       Impact factor: 2.897

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.